Addition of durvalumab, bevacizumab to TACE beneficial in liver cancer
by Elana GotkineFor patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial chemoembolization (TACE) impro
Updated on: March 22,2024
Addition of durvalumab, bevacizumab to TACE beneficial in liver cancer
by Elana GotkineFor patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial chemoembolization (TACE) impro
Updated on:March 22,2024
